Scientific publications on subjects and technologies related to Diamyd Medicals research and activities.
Publications
Data pager
Data pager
123
Show:
PageSizeComboBox
select
3 pages
March 2015
Antibodies to Inhibitory Synaptic Proteins in Neurological Syndromes Associated with Glutamic Acid Decarboxylase Autoimmunity
Nuria Gresa-Arribas, Helena Ariño, Eugenia Martínez-Hernández, Mar Petit-Pedrol, Lidia Sabater, Albert Saiz, Josep Dalmau, Francesc Graus
March 2014
GAD Autoantibody Affinity in Adult Patients With Latent Autoimmune Diabetes, the Study Participants of a GAD65 Vaccination Trial
Stephanie Krause, Ulrike Landherr, Carl-David Agardh, Simone Hausmann, Katarina Link, Jesse M. Hansen, Kristian F. Lynch, Michael Powell, Jadwiga Furmaniak, Bernard Rees-Smith, Ezio Bonifacio, Anette G. Ziegler, Åke Lernmark and Peter Achenbach
December 2013
GAD-treatment of children and adolescents with recent-onset Type 1 diabetes preserves residual insulin secretion after 30 months
Ludvigsson J, Chéramy M, Axelsson S, Pihl M, Åkerman L, Casas R; for the clinical GAD-study group in Sweden
August 2013
Glucose tolerance and beta-cell function in islet autoantibody-positive children recruited to a secondary prevention study
Andersson C, Carlsson A, Cilio C, Cedervall E, Ivarsson SA, Jonsdottir B, Jönsson B, Larsson K, Neiderud J, Lernmark A, Elding Larsson H; DiAPREV-IT Study Group
August 2013
The clinical and immunological significance of GAD-specific autoantibody and T-cell responses in type 1 diabetes
Tobias Boettlera, Philippe P. Pagnia, Rachel Jaffea, Yang Chenga, Peter Zerhouni, Matthias von Herrath
July 2013
Cellular and Humoral Immune Responses in Type 1 Diabetic Patients Participating in a Phase III GAD-alum Intervention Trial
Stina Axelsson, Mikael Chéramy, Linda Åkerman, Mikael Pihl, Johnny Ludvigsson, Rosaura Casas
June 2013
Regulatory T cell phenotype and function 4 years after GAD-alum treatment in children with type 1 diabetes
Pihl M, Akerman L, Axelsson S, Chéramy M, Hjorth M, Mallone R, Ludvigsson J, Casas R